Immunoglobulin G N-Glycans as Potential Postgenomic Biomarkers for Hypertension in the Kazakh Population

OMICS A Journal of Integrative Biology

Volumn 21, Issue 7, 2017, Pages 380-389

  Gao, Qing ^a   Dolikun, Mamatyusupu ^b   Štambuk, Jerko ^c   Wang, Hao ^a   Zhao, Feifei ^a   Yiliham, Nizam ^b   Wang, Youxin ^a   Trbojević Akmačić, Irena ^c   Zhang, Jie ^a   Fang, Honghong ^a   Sun, Yang ^a   Peng, Hongli ^a   Zhao, Zhongyao ^a   Liu, Di ^a   Liu, Jiaonan ^a   Li, Qihuan ^a   Sun, Qi ^a   Wu, Lijuan ^a   Lauc, Gordan ^c,d   Wang, Wei ^a,e   Song, Manshu ^a   more..

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b XINJIANG UNIVERSITY   (China)

^c GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e EDITH COWAN UNIVERSITY   (Australia)

Author keywords

biomarkers; Glycomics; hypertension; Kazakh population; postgenomic diagnostics

Indexed keywords

BIOLOGICAL MARKER; GLYCAN DERIVATIVE; GLYCOPEPTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; POLYSACCHARIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; KAZAKH (PEOPLE); MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PERSONALIZED MEDICINE; PREHYPERTENSION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; KAZAKHSTAN; LIQUID CHROMATOGRAPHY;

BIOMARKERS; CHROMATOGRAPHY, LIQUID; GLYCOMICS; GLYCOSYLATION; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; KAZAKHSTAN; MASS SPECTROMETRY; POLYSACCHARIDES;

EID: 85024390715     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2017.0044     Document Type: Article

References (49)

1. Ablimit A, Qin W, Shan W, et al. (2013). Genetic diversities of cytochrome B in Xinjiang Uyghur unveiled its origin and migration history. BMC Genet 14, 100.
2. Adua E, Russell A, Roberts P, et al. (2017). Innovation analysis on postgenomic biomarkers: Glycomics for chronic diseases. OMICS 21, 183-196.
3. Anthony RM, Nimmerjahn F, Ashline DJ, et al. (2008). Recapitulation of IVIG antiinflammatory activity with a recombinant IgG Fc. Science 320, 373-376.
4. Arnold JN, Wormald MR, Sim RB, et al. (2007). The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25, 21-50.
5. Bautista LE, Vera LM, Arenas IA, et al. (2005). Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 19, 149-154.
6. Black ML, Wise CA, Wang W, et al. (2006). Combining genetics and population history in the study of ethnic diversity in the People's Republic of China. Hum Biol 78, 277-293.
7. Carty DM, Schiffer E, and Delles C. (2013). Proteomics in hypertension. J Hum Hypertens 27, 211-216.
8. Clerc F, Reiding KR, Jansen BC, et al. (2016). Human plasma protein N-glycosylation. Glycoconj J 33, 309-343.
9. Cui LJ, Chang XY, Zhu LY, et al. (2016). Relationship between the polymorphisms in KCNQ1 and type 2 diabetes in Chinese Kazakh population. Genet Mol Res 15, 1-10.
10. Etxebarria J, and Reichardt NC. (2016). Methods for the absolute quantification of N-glycan biomarkers. Biochim Biophys Acta 1860, 1676-1687.
11. Ferrara C, Brunker P, Suter T, et al. (2006). Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93, 851-861.
12. GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, et al. (2015). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 2287-2323.
13. Gornik O, Wagner J, Pučić M, et al. (2009). Stability of N-glycan profiles in human plasma. Glycobiology 19, 1547-1553.
14. Hassinen A, Pujol FM, Kokkonen N, et al. (2011). Functional organization of Golgi N and O-glycosylation pathways involves pH-dependent complex formation that is impaired in cancer cells. J Biol Chem 286, 38329-38340.
15. Huang T, Chen X, Gu H, et al. (2016). Fractionation of Fab glycosylated immunoglobulin G with concanavalin a chromatography unveils new structural properties of the molecule. Oncotarget 7, 31166-31176.
16. Huffman JE, Pučić-Baković M, Klarić L, et al. (2014). Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol Cell Proteomics 13, 1598-1610.
17. Kaess BM, Rong J, Larson MG, et al. (2012). Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 308, 875-881.
18. Karsten CM, Pandey MK, Figge J, et al. (2012). Antiinflammatory activity of IgG1 mediated by Fc galactosylation and association of FccRIIB and dectin-1. Nat Med 18, 1401-1406.
19. Kearney PM, Whelton M, Reynolds K, et al. (2005). Global burden of hypertension: Analysis of worldwide data. Lancet 365, 217-223.
20. Knezević A, Polasek O, Gornik O, et al. (2009). Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res 8, 694-701.
21. Lauc G, Huffman JE, Pučić M, et al. (2013). Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet 9, e1003225.
22. Li J, Lou H,YangX, et al. (2014). Genetic architectures ofADME genes in five Eurasian admixed populations and implications for drug safety and efficacy. J Med Genet 51, 614-622.
23. Lu JP, Knežević A, Wang YX, et al. (2011). Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese Han and Croatian populations. J Proteome Res 10, 4959-4969.
24. Lundstrom SL, Yang H, Lyutvinskiy Y, et al. (2014). Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitiveimpairment. J Alzheimers Dis 38, 567-579.
25. Ma XJ, Zhang M, Guo SX, et al. (2013). Prevalence of hypertension in Uygur, Kazakhs and Han people in rural areas of Xinjiang. Clin J Hypertens 21, 1164-1168.
26. Maverakis E, Kim K, Shimoda M, et al. (2015). Glycans in the immune system and the altered glycan theory of autoimmunity: A critical review. J Autoimmun 57, 1-13.
27. Meites S, and Saniel-Banrey K. (1973). Modified glucose oxidase method for determination of glucose in whole blood. Clin Chem 19, 308-311.
28. Mihai S, and Nimmerjahn F. (2013). The role of Fc receptors and complement in autoimmunity. Autoimmun Rev 12, 657-660.
29. Molinari M. (2007). N-glycan structure dictates extension of protein folding or onset of disposal. Nat Chem Biol 3, 313-320.
30. Nikolic SB, Sharman JE, Adams MJ, et al. (2014). Metabolomics in hypertension. J Hypertens 32, 1159-1169.
31. Nimmerjahn F, and Ravetch JV. (2008). Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8, 34-47.
32. Pezer M, Stambuk J, Perica M, et al. (2016). Effects of allergic diseases and age on the composition of serum IgG glycome in children. Sci Rep 6, 33198.
33. Quast I, Keller CW, Maurer MA, et al. (2015). Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125, 4160-4170.
34. Saldova R, Asadi-Shehni A, Haakensen VD, et al. (2014). Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J Proteome Res 13, 2314-2327.
35. Sebastian A, Alzain MA, Asweto CO, et al. (2016). Glycan biomarkers for rheumatoid arthritis and its remission status in Han Chinese patients. OMICS 20, 343-351.
36. Selman MH, Derks RJ, Bondt A, et al. (2012). Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLCMS using a sheath-flow ESI sprayer interface. J Proteomics 75, 1318-1329.
37. Song MS, Zhao, FF, Ran LJ, et al. (2015). The Uyghur population and genetic susceptibility to type 2 diabetes: Potential role for variants in CDKAL1, JAZF1, and IGF1 genes. OMICS 19, 230-237.
38. Testa R, Vanhooren V, Bonfigli AR, et al. (2015). N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One 10, e0119983.
39. Trbojević Akmačić I, Ventham NT, Theodoratou E, et al. (2015). Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis 21, 1237-1247.
40. van Timmeren MM, van der Veen BS, Stegeman CA, et al. (2010). IgG glycan hydrolysis attenuates ANCAmediated glomerulonephritis. J Am Soc Nephrol 21, 1103-1114.
41. Varki A. (1993). Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3, 97-130.
42. Vučković F, Krištić J, Gudelj I, et al. (2015). Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol 67, 2978-2989.
43. Wang YX, Adua E, Russell A, et al. (2016a). Glycomics and its application potential in precision medicine. Science. DOI.org/ 10.1126/science.354.6319.1601-b.
44. Wang YX, Klarić L, Yu XW, et al. (2016b). The association between glycosylation of immunoglobulin G and hypertension. Medicine 95, e3379.
45. World Health Organization. (2013). A global brief on hypertension. http://www.who.int/entity/cardiovascular-diseases/ publications/global-brief-hypertension/en/-28k. Last access: Dec. 24, 2014.
46. Wuhrer M, Stam JC, van de Geijn FE, et al. (2007). Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 7, 4070-4081.
47. Xu DM, Li XF, Goan D, et al. (2016). Prevalence and predictors of hypertension in the labor force population in China: Results from a cross-sectional survey in Xinjiang Uygur autonomous region. Biomed Environ Sci 29, 290-294.
48. Yu XW, Wang YX, Kristic J, et al. (2016). Profiling IgG N-glycans as potential biomarker of chronological and biological ages: A community-based study in a Han Chinese population. Medicine 95, e4112.
49. Zhao FF, Mamatyusupu D, Wang YX, et al. (2016). The Uyghur population and genetic susceptibility to type 2 diabetes: Potential role for variants in CAPN10, APM1 and FUT6 genes. J Cell Mol Med 20, 2138-2147.